Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002825
Status:
COMPLETED
Last Update Posted:
2013-02-05
First Post:
1999-11-01
Brief Title:
Docetaxel in Treating Children With Recurrent Solid Tumors
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A PHASE II STUDY OF DOCETAXEL TAXOTERE NSC 628503 IN CHILDREN WITH RECURRENT SOLID TUMORS
Status:
COMPLETED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II trial to study the effectiveness of docetaxel in treating children with recurrent solid tumors Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Detailed Description:
OBJECTIVES
I Determine the response rate to docetaxel in children with recurrent sarcomas neuroblastomas or brain tumors
II Describe the toxic effects of docetaxel in these patients
OUTLINE
All patients receive docetaxel with G-CSF every 21 days for up to 12 courses Patients are followed for survival
I Determine the response rate to docetaxel in children with recurrent sarcomas neuroblastomas or brain tumors
II Describe the toxic effects of docetaxel in these patients
OUTLINE
All patients receive docetaxel with G-CSF every 21 days for up to 12 courses Patients are followed for survival
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000065008 | REGISTRY | PDQ Physician Data Query | None |
| CCG-0962 | None | None | None |